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Abstract
Acquired inhibitors to coagulation factors other than factor VIII are extremely rare. We describe a case of a 59-year-old woman with abnormal blee-
ding, diagnosed with concurrent inhibitor antibodies to factor VIII and IX by Bethesda testing. We demonstrate that anti-FVIII antibodies of a very 
high titre are capable of disturbing the aPTT-based Bethesda assay, resulting in falsely-positive antibodies to factor IX. The case also illustrates the 
usefulness of the immunological assay (ELISA) in complementing the inhibitor diagnosis.
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Acquired haemophilia is a rare condition caused 
by production of autoantibodies which inactivate 
coagulation factors. Inhibitors are most commonly 
directed to factor (F) VIII (incidence of 1,4 per mil-
lion), a condition known as acquired haemophilia 
A (1). Inhibitors to other coagulation factors are 
much less common (2,3). In 50% of cases, FVIII au-
toantibodies occur in patients lacking any relevant 
concomitant disease; the remaining cases may be 
associated with postpartum period, autoimmune 
diseases, underlying malignancy or precancerous 
states, infections, vaccinations or use of medica-
tions (4). An acquired inhibitor should be consid-
ered in patients with a recent onset of abnormal, 
often large bleeding, without prior bleeding di-
athesis (3,5). Typical laboratory findings in acquired 
haemophilia are abnormal coagulation screening 
tests, that do not correct with normal plasma, ei-
ther with immediate or incubated mix. The diag-
nosis is confirmed by assays of specific factors and 
demonstration of an inhibitor, using the original or 
Nijmegen-modified Bethesda assay (1,3). Treat-
ment is directed to both the control of bleeding 
and the elimination of the inhibitor (4).
The aim of this case report is a presentation of a 
patient with acquired haemophilia with apparent 
antibodies against both FVIII and FIX. Our hypoth-
esis was that the finding of autoantibodies against 
more than one coagulation factor is very rare so 




Blood samples of the patient for coagulation as-
says were taken into 4.5 mL BD Vacutainer tubes 
with 0.105 M trisodium citrate (Beckton, Dickinson 
and Company, Plymouth, United Kingdom). The 
blood to additive ratio was 9:1. Platelet-poor plas-
ma was prepared by centrifugation at 2000 x g for 
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15 minutes at 4 °C in a standard bench cooling 
centrifuge (Multifuge 3 S-R, Heraeus, ThermoSci-
entific, USA) (6). The first part of the laboratory 
work was done in a specialized haematology labo-
ratory, Department of Haematology, University 
Medical Centre Ljubljana, Slovenia. Small aliquots 
of samples (0.5 mL) were frozen at -20 °C and for 
long-term storage at -80 °C. Some aliquots of fro-
zen samples were sent to Laboratory of Centre for 
Thrombosis and Haemostasis, Skåne University 
Hospital in Malmö, Sweden, for further analysis.
Methods
To detect immediate or time dependent inhibi-
tion, normal plasma (Instrumentation Laboratory, 
Bedford, USA) and test plasma samples were test-
ed for activated partial thromboplastin time (aPTT) 
immediately after mixing (50:50) and also after in-
cubation at 37 °C for 120 min (6). FVIII, FIX, FXI and 
FXII activities were measured by one-stage aPTT-
based assay. Hemosil Calibration plasma, Hemosil 
APTT-SP (liquid) reagent and Hemosil factor FVIII, 
FIX, FXI and FXII deficiency plasma from Instru-
mentation Laboratory  (Bedford, USA) were used 
for preparing calibration curves and sample test-
ing. Screening (Hemosil LAC Screen, Bedford, USA) 
and confirmatory (Hemosil LAC Confirm, Bedford, 
USA) test based on dilute Rusell’s Viper Venom 
Time were used for exclusion of lupus anticoagu-
lants. All procedures were carried out according to 
manufacturer’s instructions.
In Ljubljana, Bethesda assay (6) was used to quan-
tify FVIII and FIX inhibitors. Dilutions of test plasma 
were incubated with an equal volume of the nor-
mal plasma pool (Hemosil Calibration plasma, 
Bedford, USA) at 37 °C. The normal pool plasma 
was taken to represent 1 unit of FVIII. Dilutions of a 
control normal plasma (Hemosil Calibration plas-
ma, Bedford, USA) containing no inhibitor were 
treated in the same way. An equal volume of nor-
mal plasma mixed with buffer (Hemosil Factor dil-
uent, Bedford, USA) was taken to represent the 
100 % value. At the end of the incubation period, 
the residual factor was assayed and the inhibitor 
strength was calculated from a standard graph of 
residual factor activity versus inhibitor units. The 
cut-off for positivity was set at 0.6 BU/mL. All co-
agulation tests were performed on the ACL TOP 
automated coagulation analyser (Instrumentation 
Laboratory, Bedford, USA). 
In Malmö coagulation laboratory inhibitory anti-
bodies against FVIII, FIX and FXII were analysed us-
ing the Nijmegen modified Bethesda assay (7). The 
cut-off for a positive inhibitory antibody was set at 
> 0.4 BU/mL. 
In addition, anti-human IgG specific enzyme-
linked immunosorbent assays (ELISA) were per-
formed in a manner previously described (8), using 
recombinant FVIII or FIX concentrates as antigens 
in separate assays. The cut-off for positivity was 
calculated based on the mean optical density +3 
standard deviations of samples from ten healthy 
individuals used as controls on each plate. All posi-
tive samples were analysed at least twice.
Diagnostic work-up for possible underlying disor-
ders of the patient comprised of: history taking, 
clinical examination, laboratory tests including tu-
mor markers, serological and immunological tests 
for autoimmune and infective diseases, x-ray of 
the chest and ultrasound of the abdomen.
An informed consent was obtained from the pa-
tient’s son before presenting the collected data as 
a case report. 
The approval from the national Medical Ethics 
Committee has been obtained.
Case presentation
A 59-year-old, previously healthy female patient 
was admitted to the traumatology department of 
the University Medical Centre Ljubljana, Slovenia 
after left femur neck fracture in a motorcycle acci-
dent. An unexplained coagulopathy was observed 
during and after surgery, causing vaginal bleeding 
and extensive haematomas of the right elbow, up-
per arm, and the right inguinal region. In the 
screening haemostasis tests we noticed a normal 
platelet count (197 x 109/L), a normal thrombin 
time of 15.5 s, a prolonged aPTT of 80.6 s and a 
normal prothrombin time of 0.85; mixing studies 
revealed inhibitors. FVIII and FIX activities were 
both under 0.01 IU/mL, with inhibitor titres of 358 
BU/mL and 6 BU/mL, respectively. At first blood 
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drawing we also measured low FXI (< 0.01 IU/mL) 
and FXII (0.02 IU/mL). Lupus anticoagulants were 
excluded. The patient was given recombinant fac-
tor VIIa (NovoSeven®, NovoNordisk, A/S, Bags-
vaerd, Denmark) to control the bleeding, at the 
same time the immunosuppression with methyl-
prednisolone 1 mg/kg and cyclophosphamide 100 
mg daily was started. Because of considerable 
blood loss, she received several transfusions of red 
blood cells. In two weeks’ time we noticed a sub-
sequent decline of the inhibitors, from the maxi-
mum of 389 BU/mL to 109 BU/mL for FVIII, and 
from the maximum of 7 BU/mL to 0 BU/mL for FIX. 
There were no signs of underlying malignancy, au-
toimmune diseases or infections, and no offend-
ing drugs. The results of concurrent inhibitors to 
FVIII and to FIX, the latter in a much lower titre 
than inhibitors to FVIII, detected in Ljubljana labora-
tory by Bethesda assay, are presented in Figure 1. 
By using the Bethesda-Nijmegen assay in Malmö, 
dual inhibitors in the initial blood samples of our 
patient were confirmed.  Again, FVIII inhibitor ti-
tres were much higher (from 73 to 217 BU/mL) 
than FIX inhibitor titres (2.5 to 4 BU/mL). 
ELISA, using recombinant FIX and FVIII concen-
trates as antigens, revealed positive antibodies 
against FVIII only. 
Subsequently, a Bethesda-Nijmegen mixing ex-
periment with FXII-deficient plasma instead of FIX 
was performed; again a positive anti-FXII titre of 4 
BU/mL was found, exactly the same as obtained 
previously for FIX.  Additionally, a sample from an-
other patient with a very high anti-FVIII inhibitor 
titre of 1429 BU/mL from the Malmö hospital 
(“Malmö patient” in Table 1) was analysed and re-
sulted in an anti-FIX Bethesda titre of 14 BU/mL. 
The results of our patient’s samples, together with 
the “Malmö patient”, all of which were tested in 
the Malmö Laboratory, are presented in Table 1. 
Presented are results of the Nijmegen-Bethesda 
assay and ELISA.
The immunosuppression was tapered until four 
months later, when it was discontinued because of 
a postoperative wound infection. At that point FVIII 
activity was 0.03 IU/ml with an antibody titre of 3 
BU/mL, while FIX activity was normal (1.31 IU/ml). In 
the following three years we observed a spontane-
ous rise of FVIII activity to a maximum of 0.15 IU/
mL, with inhibitor titres falling from 6 to 0.7 BU/
mL. During that time the patient suffered only one 
bleeding, namely haemarthrosis of the left knee, 
which was treated with 3 doses of NovoSeven.
Because of the patient’s constant pain in the left 

















No .1 152 2.5 pos neg ND
No .2 204 4 pos neg 4
No .3 217 4 pos neg ND
No .4 73 0 pos neg ND
“Malmo 
patient” 1429 14 pos neg ND
Samples No. 1-4 were taken from our patient on day 1 (Sample 
No.1), day 4 (Sample No.2), day 5 (Sample No.3) and day 14 
(Sample No.4) of treatment. “Malmö patient”- a patient from 
the Malmö coagulation laboratory with a very high FVIII 
inhibitor titre. ND – not determined, pos – positive, neg – 
negative.
Table 1. Inhibitor antibodies of our patient (Samples No.1-4) 
and  the “Malmö patient”, measured by Bethesda-Nijmegen as-
say and ELISA assay in Malmö coagulation laboratory
Figure 1. Titres of anti-FVIII and anti-FIX antibodies in our pa-
tient, measured by Bethesda assay in Ljubljana. Titres of anti-
FVIII approximately 110 BU/mL and higher are accompanied by 
anti-FIX titres, although in a much lower titre (assuming that the 
cut-off for positive anti-FIX is 0.6 BU/mL). A dose-dependent ef-
fect of anti-FVIII antibodies on the anti-FIX assay is demonstrat-
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planned. With the intention of preoperative eradi-
cation of the remaining inhibitors, four doses of 
rituximab 375 mg/m2 weekly were prescribed, 
which ultimately led to a complete eradication of 
FVIII inhibitors, three years and a half after initial 
diagnosis.
An inoperable metastatic neuroendocrine micro-
cellular lung carcinoma was diagnosed a year later, 
causing the patient`s death.
Discussion
With this case report we demonstrate that a pa-
tient, initially diagnosed with concurrent inhibitors 
to both FVIII and FIX, actually had only inhibitors 
to FVIII. Secondly, we show that clotting assays, 
such as Bethesda or Nijmegen-modified Bethesda 
assay can give us false results. We confirm the fact 
described previously, that an inhibitor to a single 
clotting factor can interfere with the assays of oth-
er coagulation factors, selectively reducing the tar-
get factor but there may be some apparent reduc-
tion in other factor levels due to an inhibitory ef-
fect on the factor deficient plasma used in the as-
say (5). This is best documented with FVIII inhibi-
tors, where all intrinsic factors may apparently be 
low due to inhibition of FVIII in the intrinsic factor-
deficient plasma. In such cases, serial dilution 
should result in a correction of the non-specifically 
reduced factors while the specifically reduced fac-
tors should remain low (3,9). We have indeed 
measured decreased FVIII (< 0.01 IU/mL), FIX (< 
0.01 IU/mL), FXI (< 0.01 IU/mL) and FXII (0.02 IU/mL) 
in the initial samples from our patient by using the 
one-stage aPTT assay. 
As the majority of acquired antibodies are direct-
ed against FVIII (2), acquired inhibitors to factor IX 
are only occasionally reported (10-14). Similarly, to 
FVIII autoantibodies, they seem to occur more fre-
quently in association with autoimmune disorders 
or postpartum (15).  In contrast to FVIII inhibitors, 
which may show a time dependency for inhibi-
tion, FIX inhibitors are immediate-acting (3,5). Ini-
tial results of concurrent inhibitors to FVIII and FIX, 
diagnosed by Bethesda assay (6) in Ljubljana were 
met with scepticism. However, the finding of dual 
inhibitors was confirmed in Malmö, using the 
Bethesda-Nijmegen assay protocol (7), which is 
supposed to better discriminate between positive 
and negative samples at the lower range (3,9,16). 
Similarly, to results obtained in Ljubljana, FVIII in-
hibitor titres were much higher (from 73 to 217 BU/
mL) than FIX inhibitor titres (2.5 to 4 BU/mL).
ELISA, performed in a manner previously de-
scribed (8), using recombinant FVIII or FIX concen-
trates as antigens, confirmed our assuming that 
the dual Bethesda positivity was an in vitro finding. 
The results indicated a strong positivity for anti-
FVIII IgG, but not for the antibodies against FIX. 
According to the literature, false detection of in-
hibitor antibodies is not so rare, reported in up to 
30% of samples analysed by Nijmegen assay (17) 
and a common reason for results similar to ours is 
heparin contamination of the sample (18).
When suspecting an acquired haemophilia, it is 
also important to rule out lupus anticoagulants as 
a possible reason for prolonged aPTT (1,3). On the 
contrary, lupus anticoagulants usually cause 
thrombosis, not bleeding. They can sometimes 
mimic FVIII inhibitors, which results in a decrease 
of most of coagulation factors. An ELISA test for 
FVIII inhibitor screening is often advised when 
phospholipid antibodies interfere with the Bethes-
da assay (4). Favaloro et al. advise using ELISA in all 
cases in which clot-based assays may be influ-
enced by the presence of other antibodies or by 
heparin contamination from venous access devic-
es. Clot-based assays are less sensitive than ELISA 
assays, but the ELISA assays, in contrast, lack speci-
ficity because they detect both inhibitory and 
non-inhibitory (so-called ‘non-neutralising’) anti-
bodies (17). 
Figure 1 demonstrates the measured titres of anti-
FVIII and anti-FIX antibodies, obtained by using 
the Bethesda assay in Ljubljana laboratory. A dose-
dependent effect of anti-FVIII antibodies on the 
anti-FIX assay can be observed, i.e. the risk of get-
ting false positive anti-FIX results increases with 
the titre of anti-FVIII inhibitors. In our case the dual 
positivity (false positive anti-FIX antibodies) is ap-
parent above approx. 110 BU/mL of anti-FVIII, as-
suming that the cut-off for positive anti-FIX is 0.6 
BU/mL. A similar graph was obtained using titres 
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of antibodies, measured by Nijmegen-Bethesda 
assay in the Laboratory in Malmö. 
To our best knowledge there are only three re-
ports in the literature describing concurrent inhib-
itors to factor VIII and IX (19-21). Shen et al. de-
scribed a 14-year-old girl with systemic lupus ery-
thematosus, presenting with ecchymoses and 
macrohematuria. To attenuate the effect of the FIX 
inhibitor on the FVIII measurement, the factor as-
says were repeated at higher serial dilutions of the 
patient’s plasma with FVIII deficient plasma, and 
vice versa. Inhibitors of FVIII and FIX showed posi-
tive findings with 6 and 4 Bethesda units, respec-
tively (19). Brasilian authors presented a case of a 
52-year-old man with chronic hepatitis C, who re-
ceived antiviral treatment with pegylated interfer-
on plus ribavirin (20). In this patient, inhibitor anti-
bodies against FVIII were detected in a 70-times 
higher titre than the inhibitors to FIX. Similarly, to 
our case, the much lower titre of anti-FIX antibod-
ies could have been an artefact, caused by a dis-
turbance of the Bethesda assay by a high titre of 
anti-FVIII antibodies. Carmassi and colleagues re-
port a case of a 64-year-old man with a history of 
cutaneous vasculitis and Sjögren syndrome, pre-
senting with extensive muscular and subcutane-
ous haematomas. FVIII and FIX activities were 0.05 
IU/mL and 0.56 IU/mL, respectively, and the corre-
sponding inhibitor titres for FVIII and FIX were 25 
BU/mL and 7 BU/mL, respectively. To prevent the 
interference of FVIII inhibitors on FIX, the authors 
performed the assay at multiple dilutions (21). The 
ELISA test was not performed in any of the three 
reports. Our study is yielding possible explanation 
of the above described results. The strength of our 
study is utilisation of both the classical Bethesda 
and the Nijmegen modification of the Bethesda 
assay; the use of the latter is supposed to reduce 
weak false positive inhibitor titres. An additional 
advantage is the utilisation of ELISA, which finally 
discriminates between truly and falsely positive 
antibodies.
The limitations of our study are that we did not 
perform all the tests, since we did not plan to pub-
lish the case at that time. In Ljubljana we checked 
only inhibitors to FVIII and FIX as those are the 
most common (15, 22). When we obtained positive 
anti-FIX and anti-FXII antibodies by Nijmegen-
Bethesda assay, we did not measure anti-FXI anti-
bodies by Bethesda-Nijmegen assay, however we 
expected them to be positive too. When analysing 
the “Malmo” patient, we also performed only anti-
FVIII and anti-FIX antibodies but nothing else after 
negative anti-FIX by ELISA. 
In conclusion, we have shown that anti-FVIII anti-
bodies of a very high titre are capable of disturb-
ing an aPTT-based neutralization assay such as 
Bethesda, which results in falsely positive antibod-
ies to other coagulation factors. An important 
message is not to rely on a single Bethesda assay 
test result. To avoid identification of false inhibitors 
we must keep in mind that acquired antibodies to 
FVIII are by far the most common (1). Sometimes a 
clue for the “true” inhibitor is obtained by the “rel-
ative” deficiencies observed (e.g., a FVIII level that 
is undetectable and detectable but low FIX, FXI 
and/or FXII is likely to be a FVIII inhibitor) (5). How-
ever, this was not the case in our patient. Our case 
report illustrates the usefulness of immunological 
assays to complement the inhibitor diagnosis. 
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